ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 15 of 56
Up
JMBS 2018, 3(6): 83–87
https://doi.org/10.26693/jmbs03.06.083
Clinical Medicine

Optimization of Treating Nonalcoholic Steatohepatitis with Obesity and Chronic Kidney Disease of the I-II Stages

Antoniv A. A.
Abstract

The purpose of the study was to improve the treatment of non-alcoholic steatohepatitis with obesity and chronic kidney disease of the I-II stages by studying the effect of S-adenosylmethionine on the course of these pathologies. Material and methods. We examined 140 patients with non-alchoholic steatohepatitis with comorbid obesity of the 1st degree and chronic kidney disease of the 1st and 2nd stages. To determine the efficacy of the treatment, 2 groups of patients were randomized according to age, sex, degree of obesity, activity of the cytolytic syndrome of non-alchoholic steatohepatitis and the stage of the chronic kidney disease (chronic uncomplicated pyelonephritis with latent course in the phase of subsiding acute exacerbation). Control group (1) (72 patients) received a hypocaloric diet, metformin 500 mg twice daily, Essentiale H as a hepatoprotective drug (1 capsule 3 times a day), canephron (50 mg 3 times a day) during 90 days. The second group (2) (68 patients) received a hypocaloric diet, metformin 500 mg twice daily, canephron (50 mg 3 times a day), adenosylmethionine (Ahepta) (SAM) as a hepatoprotective drug (200 mg 3 times on a sublingual day) during 90 days. Results and discussion. In the dynamics of treating Adenosylmethionine (Agepta) (SAM), we noticed a significant increase in the liver protein function (albumen content in group 2 increased 1.3 times (p <0.05) versus 7.7% (p> 0.05) in group 1). The probable increase in the total protein content in blood increased 1.3 times (p <0.05) against 1.2 times in group 1, respectively, 3 months after treatment (p <0.05). Thus, SAM possesses powerful membrane-stabilizing properties, stably eliminates the manifestations of cytolysis, cholestasis, mesenchymal-inflammatory syndrome, increases the albumin-synthesizing function of the liver in patients with Nonalcoholic Steatohepatitis (NASH) and prevents the loss of albumins in the conditions of Chronic Kidney Disease of the I-II Stages. The obtained results showed that complex therapy of patients with non-alcoholic steatohepatitis with obesity and chronic kidney disease of the I-II stages, including S-adenosylmethionine, stably eliminates clinical manifestations of the disease, the intensity of cytolysis, cholestasis, mesenchymal-inflammatory syndrome, inhibits the progression of hepatic and renal dysfunction by optimizing the control of fibrosis of the liver and kidneys. Conclusion. Optimization of curing patients with non-alcoholic steatohepatitis with obesity and chronic kidney disease of the I-II stages, including S-adenosylmethionine, is superior to the correction of clinical syndromes of non-alcoholic steatohepatitis and chronic kidney disease.

Keywords: nonalcoholic steatohepatitis, chronic kidney disease, obesity, treatment

Full text: PDF (Ukr) 198K

References
  1. Babak OYa, Kolesnikova EV, Syitnik KA. Profilakticheskie meropriyatiya pri nealkogolnoy zhirovoy bolezni pecheni: suschestvuet li sposob snizit risk razvitiya zabolevaniya? [Preventive measures for non-alcoholic fatty liver disease: is there a way to reduce the risk of the disease?]. Suchasna gastroenterol. 2013; 3(71): 103-9. [Russian]
  2. Bueverov AO, Bogomolov PO. Nealkogol'naya zhirovaya bolezn' pecheni: obosnovanie patogeneticheskoy terapii [Non-alcoholic fatty liver disease: rationale for pathogenetic therapy]. Klinicheskie perspektivy v gastroenterologii, gepatologii. 2009; 1: 3-9. [Russian]
  3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-44. https://www.ncbi.nlm.nih.gov/pubmed/23507799. https://doi.org/10.1038/nrgastro.2013.41
  4. Ekstedt M, Franzén LE, Mathiesen UL. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007; 47(1): 135-41. https://www.ncbi.nlm.nih.gov/pubmed/17400325. https://doi.org/10.1016/j.jhep.2007.02.013
  5. Georgescu EF. Angiotensin receptor blockers in the treatmentof NASH/NAFLD: couldtheybe a first-classoption? Adv Ther. 2008; 25(11): 1141-74. https://www.ncbi.nlm.nih.gov/pubmed/18972077. https://doi.org/10.1007/s12325-008-0110-2
  6. Abenavoli L, Peta V. Role оf adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials. 2014; 9(Suppl 3): 134-40. https://www.ncbi.nlm.nih.gov/pubmed/25514909
  7. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J of Hepatol. 2012; 57(Iss 5): 1097-109.
  8. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10(11): 666–75. https://www.ncbi.nlm.nih.gov/pubmed/24061203. https://doi.org/10.1038/nrgastro.2013.175
  9. Cederbaum А. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol. 2010; 16(11): 1366-76. https://www.ncbi.nlm.nih.gov/pubmed/20238404. https://www.ncbi.nlm.nih.gov/pmc/articles/2842529
  10. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-44. https://www.ncbi.nlm.nih.gov/pubmed/23507799. https://doi.org/10.1038/nrgastro.2013.41
  11. Kowdley KV. Advances in the diagnosis and treatment of nonalcoholic steatohepatitis. Gastroenterol. Hepatol (NY). 2014; 10(3): 184–6. https://www.ncbi.nlm.nih.gov/pubmed/24829546. https://www.ncbi.nlm.nih.gov/pmc/articles/ 4014051
  12. Lam В, Younossi ZM. Treatment options for nonalcoholic fatty liver diseasе. Therap Adv Gastroenterol. 2010; 3(2): 121–37. https://www.ncbi.nlm.nih.gov/pubmed/21180596. https://www.ncbi.nlm.nih.gov/pmc/articles/3002571. https://doi.org/10.1177/1756283X09359964
  13. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exper Biol and Med. 2015; 240(6): 809–20. https://www.ncbi.nlm.nih.gov/pubmed/25873078. https://www.ncbi.nlm.nih.gov/pmc/articles/4818965. https://doi.org/10.1177/1535370215579161